Editorial & Review Policy¶
This page explains who writes the content on this knowledge base, how it is reviewed, what standards it must meet, and how you can report an error. Migibio publishes technical medical content, so we hold it to a documented editorial standard — not a marketing standard.
1. Who Writes Our Content¶
Content is produced by the Migibio Clinical & Scientific Affairs team, composed of:
- Biomedical and immunoassay development engineers who work directly on the FICT platform.
- Regulatory-affairs specialists responsible for ISO 13485-aligned quality documentation, IFU (Instructions for Use), and COA (Certificate of Analysis) authoring.
- Application scientists who train distributors and validate assays against clinical samples.
Writers are named at the organization level (Migibio Clinical & Scientific Affairs) rather than as individuals, because our content is a corporate technical deliverable reviewed through a defined committee process. We do not attribute content to fabricated individual authors.
2. Who Reviews Our Content¶
Every page is reviewed by the Migibio R&D Quality Committee before publication. The review checks:
| Review gate | What is verified |
|---|---|
| Technical accuracy | Analyzer specifications, assay parameters, reference ranges match current IFU and validation data |
| Clinical correctness | Interpretation guidance aligns with current veterinary guidelines (e.g., IRIS CKD staging) |
| Regulatory compliance | Claims do not overstate intended use; no unapproved diagnostic or therapeutic claims |
| Source integrity | Every quantitative claim traces to a citable source (internal validation report, published literature, or recognized guideline) |
Content is re-reviewed whenever a product specification, reference range, or referenced guideline changes.
3. Citation & Evidence Standards¶
- Quantitative claims (reference ranges, LOD, CV%, sensitivity/specificity) must cite either an internal Migibio validation report or a recognized external source.
- Clinical interpretation references recognized veterinary guidelines where they exist — for example, the IRIS (International Renal Interest Society) staging system for chronic kidney disease and ACVIM (American College of Veterinary Internal Medicine) consensus statements.
- Where a claim is specific to Migibio's own assay (e.g., a product's analytical LOD), it is labeled as a Migibio validation figure rather than an industry-universal value.
4. Conflict of Interest¶
Migibio (Guangzhou Magic Biotech Co., Ltd.) is the manufacturer of the FIA680/FIA880 analyzers and the FICT test reagents described on this site. This is a manufacturer-published technical resource. We disclose this relationship on every page and in our structured data (schema.org publisher/author fields).
We do not:
- Publish content from third parties in exchange for favorable placement.
- Suppress known limitations — limitations sections are mandatory on technology and assay pages.
5. Correction Policy¶
If you find an error, email [email protected] with the page URL and the specific issue. Corrections are logged, reviewed by the R&D Quality Committee, and applied within a reasonable review cycle. Material corrections that could affect clinical interpretation are prioritized.
6. Scope & Separation From Regulated Claims¶
This knowledge base is a technical reference for trained veterinary professionals. It is not a substitute for the official Instructions for Use (IFU) shipped with each product, which is the legally controlling document. Where this site and the IFU differ, the IFU governs.
Last reviewed: 2026-08-13 by the Migibio R&D Quality Committee.
Authored by: Migibio Clinical & Scientific Affairs, Guangzhou Magic Biotech Co., Ltd.
Reviewed by: Migibio R&D Quality Committee
Last updated: 2026-08-13
Disclosure: Migibio (Guangzhou Magic Biotech Co., Ltd.) is the manufacturer of the FIA680/FIA880 analyzers and FICT reagents referenced in this content. See our Editorial & Review Policy.